The detection of measurable residual disease (MRD) is the strongest predictor of relapse in acute lymphoblastic leukemia (ALL). Using inotuzumab ozogamicin in the setting of MRD may improve outcomes. Patients with ALL in first complete remission (CR1) or beyond (CR2+) with MRD ≥1x10-4 were enrolled in this phase II trial. Inotuzumab was administered at 0.6 mg/m2 on Day 1 and 0.3 mg/m2 on Day 8 of cycle 1, then at 0.3 mg/m2 on Days 1 and 8 of cycles 2-6. Twenty-six consecutive patients with …